Equities analysts predict that IDEAYA Biosciences (NASDAQ:IDYA) will post ($0.67) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for IDEAYA Biosciences’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.77). The company is scheduled to issue its next quarterly earnings report on Monday, November 11th.
On average, analysts expect that IDEAYA Biosciences will report full-year earnings of ($2.65) per share for the current fiscal year, with EPS estimates ranging from ($3.06) to ($1.75). For the next year, analysts expect that the company will post earnings of ($3.13) per share, with EPS estimates ranging from ($4.13) to ($2.01). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover IDEAYA Biosciences.
IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Monday, August 12th. The company reported ($1.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.66).
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new position in IDEAYA Biosciences in the second quarter valued at about $49,000. BlackRock Inc. acquired a new position in IDEAYA Biosciences in the second quarter worth about $82,000. Laurion Capital Management LP acquired a new position in IDEAYA Biosciences in the second quarter worth about $199,000. Vanguard Group Inc. acquired a new position in IDEAYA Biosciences in the second quarter worth about $349,000. Finally, Monashee Investment Management LLC acquired a new position in IDEAYA Biosciences in the second quarter worth about $354,000. Hedge funds and other institutional investors own 25.12% of the company’s stock.
Shares of IDEAYA Biosciences stock opened at $5.79 on Friday. The company has a current ratio of 18.94, a quick ratio of 18.95 and a debt-to-equity ratio of 0.05. IDEAYA Biosciences has a 12-month low of $4.89 and a 12-month high of $16.90. The stock has a 50-day moving average price of $7.05.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.